Cibc Asset Management Inc Ionis Pharmaceuticals Inc Transaction History

Cibc Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$43.39 - $51.63 $173,646 - $206,623	4,002 New	4,002 $202,000
Q3 2022 Nov 03, 2022	BUY	$36.54 - $48.66 $190,117 - $253,177	5,203 New	5,203 $230,000
Q2 2022 Aug 09, 2022	SELL	$31.71 - $43.0 $177,036 - $240,069	-5,583 Closed	0 $0
Q1 2022 May 06, 2022	BUY	$29.88 - $37.04 $166,820 - $206,794	5,583 New	5,583 $207,000
Q3 2021 Nov 09, 2021	SELL	$33.54 - $40.55 $172,395 - $208,426	-5,140 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$42.51 - $63.78 $4,506 - $6,760	-106 Reduced 2.02%	5,140 $231,000
Q3 2020 Nov 05, 2020	BUY	$47.45 - $62.95 $6,168 - $8,183	130 Added 2.54%	5,246 $249,000
Q4 2019 Feb 14, 2020	BUY	$53.85 - $65.27 $33,010 - $40,010	613 Added 13.61%	5,116 $309,000
Q3 2018 Nov 02, 2018	BUY	$42.88 - $53.7 $193,088 - $241,811	4,503 New	4,503 $232,000
Q1 2018 Apr 30, 2018	SELL	$44.08 - $55.05 $184,695 - $230,659	-4,190 Closed	0 $0
Q3 2017 Nov 06, 2017	BUY	$45.56 - $59.57 $190,896 - $249,598	4,190	4,190 $212,000

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.